832-497-2220 [email protected]

News and Blog

»News and Blog

CDK4/6 inhibitor for small cell lung cancer is launched in the U.S., Simcere has development rights in Greater China

Recently the CDK4/6 inhibitor Cosela (trilaciclib), developed by G1Therapeutics, was launched in the United States. The inhibitor’s aim is to “decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)”. The product is expected to enter the market in March.

Industry research | Review of bladder cancer immunotherapy treatments and market opportunity analysis

Bladder cancer occurs when cells that comprise the urinary bladder begin to grow out of control. Over time, as more cancer cells develop, they can form a tumor and spread to other parts of the body. The most common type of bladder cancer, according to the American Cancer Society, is urothelial carcinoma, or transitional cell carcinoma (TCC). It begins in the urothelial cells that line the interior of the bladder.

Industrial Park Insights | Changsha High-tech Industrial Development Zone (CSHTZ) builds a biomedical industry area

Changsha High-tech Industrial Development Zone (CSHTZ) was established in 1988 and was included within the first batch of national-level high-tech industrial development zones in 1991. It includes the core industrial park of Yuelu Mountain High-tech Park, or Luvalley, which is located on the western bank of Xiangjiang River and on the north side of Mount Lu. The planned area is 140 square kilometers.

Industrial Park Insights | Daxing Biomedicine Industry Park (CBP) Enters Rapid Biomedical Industry Development

The biomedical industry has spurred global economic development, and more and more countries around the world are attaching great importance to the innovative development of this industry. As one of the strategic emerging industries, in China three major industrial clusters of biomedical research have developed in the Yangtze River Delta, the Bohai Rim, and the Guangdong-Hong Kong-Macao Greater Bay Area. In addition, Hubei in central China and Chengdu and Chongqing in the West also show a good industrial foundation.

Industry Research | Global Dry Eye Market Review and Opportunity Analysis

Dry eye is an ophthalmological disease where a person’s eyes either don’t produce enough tears, or if they don’t make the right kind of tears. According to the American Optometric Association, there can be multiple contributing factors to dry eyes, including age, gender, medications, medical conditions, and environmental conditions. Symptoms include a stinging, burning, or scratching sensation, blurred vision, stringy mucus near the eye, redness, light sensitivity, and watery eyes. If timely and effective treatment is not taken, it can cause inflammation and damage to the surface of the eye, easily developing intractable dry eye, and even blindness. At present, dry eye is the most common disease represented in ophthalmology clinics, accounting for 70% of all eye diseases. It is estimated that, on average, one in five people has dry eye.

2020 Top Ten Chinese Biomedicine Licensing-in Agreements

In China, licensing in has become a key link in the new drug research and development industry chain. Licensing is when one company gives another company permission for a specific period of time to manufacture its product in return for an agreed-upon payment. In this example, the company giving permission is a foreign one and the one doing the manufacturing is Chinese. The process includes granting permission to intellectual property rights under defined conditions.
On the one hand, licensing can make up for the shortcomings of the manufacturing company’s product line, on the other hand, multinational pharmaceutical companies also rely on authorizing research projects to improve their products, promote the Chinese market, or integrate existing businesses.

Exclusive Interview | Interview of Senior Executives at Kintor Pharmaceutical

In the 11 years from its debut in 2009 to its IPO on the Hong Kong Stock Exchange in 2020, Kintor Pharmaceutical has had 5 clinical-stage products under development and carried out multiple phase I-III clinical trials across three continents covering a broad spectrum of diseases. The drug candidates include second-generation androgen receptor (AR) antagonist Proxalutamide, AR antagonist Pyrilutamide, fully human monoclonal antibody GT90001 (ALK-1), and others. The milestones that Kintor has achieved are due to team members’ perseverance, insight into market demand and the embracing of team diversity.

Today’s interviewees are from the Kintor executive team. One was an investment bank elite and the other is a doctor who returned to China after working in the US.